Carriage of Streptococcus pneumoniae and Other Respiratory Bacterial Pathogens in Low and Lower-Middle Income Countries: A Systematic Review and Meta …

RA Adegbola, R DeAntonio, PC Hill, A Roca, E Usuf… - PloS one, 2014 - journals.plos.org
Background Infection with Streptococcus pneumoniae is a major cause of childhood
morbidity and mortality worldwide, especially in low income countries where pneumococcal …

[HTML][HTML] Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an …

PA Waight, NJ Andrews, SN Ladhani… - The Lancet infectious …, 2015 - thelancet.com
Background The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key
serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7) …

A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults

JD Chalmers, J Campling, A Dicker… - BMC pulmonary …, 2016 - Springer
Background Invasive pneumococcal disease (IPD) and pneumococcal pneumonia are
common and carry a significant morbidity and mortality. Current strategies to prevent …

Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland

H Rinta-Kokko, AA Palmu, K Auranen, JP Nuorti… - Vaccine, 2018 - Elsevier
Background The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into
the Finnish National Vaccination Programme (NVP) in September 2010. The impact of …

Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+ 1 to 1+ 1 in England and Wales: A modelling study

YH Choi, N Andrews, E Miller - PLoS medicine, 2019 - journals.plos.org
Background In October 2017, the United Kingdom Joint Committee on Vaccination and
Immunisation (JCVI) recommended removal of one primary dose of the 13-valent …

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis

MH Rozenbaum, AJ Van Hoek, D Fleming, CL Trotter… - Bmj, 2012 - bmj.com
Objective To estimate the cost effectiveness of vaccinating people with high risk conditions
against invasive pneumococcal disease using the 13 valent pneumococcal conjugate …

Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study

S Flasche, M Lipsitch, J Ojal, A Pinsent - BMC medicine, 2020 - Springer
Background Herd protection through interruption of transmission has contributed greatly to
the impact of pneumococcal conjugate vaccines (PCVs) and may enable the use of cost …

[HTML][HTML] Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands

AMM van Deursen, SP van Mens… - Emerging infectious …, 2012 - ncbi.nlm.nih.gov
In the Netherlands, the national immunization program includes 7-valent pneumococcal
conjugate vaccine (PCV7) for all newborns born after April 1, 2006. We compared the …

Age-Dependent Prevalence of Nasopharyngeal Carriage of Streptococcus pneumoniae before Conjugate Vaccine Introduction: A Prediction Model Based on a Meta …

O Le Polain de Waroux, S Flasche, D Prieto-Merino… - PloS one, 2014 - journals.plos.org
Introduction Data on the prevalence of nasopharyngeal carriage of S. pneumoniae in all age
groups are important to help predict the impact of introducing pneumococcal conjugate …

Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in …

S Flasche, J Ojal, O Le Polain de Waroux, M Otiende… - BMC medicine, 2017 - Springer
Abstract Background The World Health Organisation recommends the use of catch-up
campaigns as part of the introduction of pneumococcal conjugate vaccines (PCVs) to …